These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 30422728)
1. The investigation of protective effects of glucagon-like peptide-1 (GLP-1) analogue exenatide against glucose and fructose-induced neurotoxicity. Khalilnezhad A; Taskiran D Int J Neurosci; 2019 May; 129(5):481-491. PubMed ID: 30422728 [TBL] [Abstract][Full Text] [Related]
2. Enhancing the GLP-1 receptor signaling pathway leads to proliferation and neuroprotection in human neuroblastoma cells. Li Y; Tweedie D; Mattson MP; Holloway HW; Greig NH J Neurochem; 2010 Jun; 113(6):1621-31. PubMed ID: 20374430 [TBL] [Abstract][Full Text] [Related]
3. Mechanism of the neuroprotective effect of GLP-1 in a rat model of Parkinson's with pre-existing diabetes. Elbassuoni EA; Ahmed RF Neurochem Int; 2019 Dec; 131():104583. PubMed ID: 31654678 [TBL] [Abstract][Full Text] [Related]
4. Protective effects of the GLP-1 mimetic exendin-4 in Parkinson's disease. Athauda D; Foltynie T Neuropharmacology; 2018 Jul; 136(Pt B):260-270. PubMed ID: 28927992 [TBL] [Abstract][Full Text] [Related]
5. Glucagon-like peptide-1 protects hippocampal neurons against advanced glycation end product-induced tau hyperphosphorylation. Chen S; An FM; Yin L; Liu AR; Yin DK; Yao WB; Gao XD Neuroscience; 2014 Jan; 256():137-46. PubMed ID: 24183963 [TBL] [Abstract][Full Text] [Related]
6. Exendin-4 protects against high glucose-induced mitochondrial dysfunction and oxidative stress in SH-SY5Y neuroblastoma cells through GLP-1 receptor/Epac/Akt signaling. Pandey S; Mangmool S; Madreiter-Sokolowski CT; Wichaiyo S; Luangmonkong T; Parichatikanond W Eur J Pharmacol; 2023 Sep; 954():175896. PubMed ID: 37391007 [TBL] [Abstract][Full Text] [Related]
7. Exenatide Reverts the High-Fat-Diet-Induced Impairment of BDNF Signaling and Inflammatory Response in an Animal Model of Alzheimer's Disease. Bomba M; Granzotto A; Castelli V; Onofrj M; Lattanzio R; Cimini A; Sensi SL J Alzheimers Dis; 2019; 70(3):793-810. PubMed ID: 31256135 [TBL] [Abstract][Full Text] [Related]
8. Novel incretin analogues improve autophagy and protect from mitochondrial stress induced by rotenone in SH-SY5Y cells. Jalewa J; Sharma MK; Hölscher C J Neurochem; 2016 Oct; 139(1):55-67. PubMed ID: 27412483 [TBL] [Abstract][Full Text] [Related]
9. Exenatide upregulates gene expression of glucagon-like peptide-1 receptor and nerve growth factor in streptozotocin/nicotinamide-induced diabetic mice. Gumuslu E; Cine N; Ertan M; Mutlu O; Komsuoglu Celikyurt I; Ulak G Fundam Clin Pharmacol; 2018 Apr; 32(2):174-180. PubMed ID: 29091313 [TBL] [Abstract][Full Text] [Related]
10. Neuroprotective and anti-apoptotic effects of liraglutide on SH-SY5Y cells exposed to methylglyoxal stress. Sharma MK; Jalewa J; Hölscher C J Neurochem; 2014 Feb; 128(3):459-71. PubMed ID: 24112036 [TBL] [Abstract][Full Text] [Related]
11. Liraglutide prevents beta-amyloid-induced neurotoxicity in SH-SY5Y cells via a PI3K-dependent signaling pathway. Liu XY; Wang LX; Chen Z; Liu LB Neurol Res; 2016 Apr; 38(4):313-9. PubMed ID: 27108910 [TBL] [Abstract][Full Text] [Related]
12. A GLP-2 Analogue Protects SH-SY5Y and Neuro-2a Cells Against Mitochondrial Damage, Autophagy Impairments and Apoptosis in a Parkinson Model. Su Y; Zhang Z; Li H; Ma J; Sun L; Shao S; Zhang Z; Hölscher C Drug Res (Stuttg); 2021 Jan; 71(1):43-50. PubMed ID: 33022720 [TBL] [Abstract][Full Text] [Related]
13. Protective Effect of Neuropeptide Apelin-13 on 6-Hydroxydopamine-Induced Neurotoxicity in SH-SY5Y Dopaminergic Cells: Involvement of Its Antioxidant and Antiapoptotic Properties. Pouresmaeili-Babaki E; Esmaeili-Mahani S; Abbasnejad M; Ravan H Rejuvenation Res; 2018 Apr; 21(2):162-167. PubMed ID: 28782414 [TBL] [Abstract][Full Text] [Related]
14. Effect of exenatide on postprandial glucose fluxes, lipolysis, and ß-cell function in non-diabetic, morbidly obese patients. Camastra S; Astiarraga B; Tura A; Frascerra S; Ciociaro D; Mari A; Gastaldelli A; Ferrannini E Diabetes Obes Metab; 2017 Mar; 19(3):412-420. PubMed ID: 27898183 [TBL] [Abstract][Full Text] [Related]
15. Biological activity of AC3174, a peptide analog of exendin-4. Hargrove DM; Kendall ES; Reynolds JM; Lwin AN; Herich JP; Smith PA; Gedulin BR; Flanagan SD; Jodka CM; Hoyt JA; McCowen KM; Parkes DG; Anderson CM Regul Pept; 2007 Jun; 141(1-3):113-9. PubMed ID: 17292977 [TBL] [Abstract][Full Text] [Related]
16. Pharmacology of the glucagon-like peptide-1 analog exenatide extended-release in healthy cats. Rudinsky AJ; Adin CA; Borin-Crivellenti S; Rajala-Schultz P; Hall MJ; Gilor C Domest Anim Endocrinol; 2015 Apr; 51():78-85. PubMed ID: 25594949 [TBL] [Abstract][Full Text] [Related]
17. Attenuation of carotid neointimal formation after direct delivery of a recombinant adenovirus expressing glucagon-like peptide-1 in diabetic rats. Lim S; Lee GY; Park HS; Lee DH; Tae Jung O; Kyoung Min K; Kim YB; Jun HS; Hak Chul J; Park KS Cardiovasc Res; 2017 Feb; 113(2):183-194. PubMed ID: 27702762 [TBL] [Abstract][Full Text] [Related]
18. Long-term metabolic and hormonal effects of exenatide on islet transplant recipients with allograft dysfunction. Faradji RN; Froud T; Messinger S; Monroy K; Pileggi A; Mineo D; Tharavanij T; Mendez AJ; Ricordi C; Alejandro R Cell Transplant; 2009; 18(10):1247-59. PubMed ID: 20003758 [TBL] [Abstract][Full Text] [Related]
19. Glucagon-like peptide-1 and islet lipolysis. Sörhede Winzell M; Ahrén B Horm Metab Res; 2004; 36(11-12):795-803. PubMed ID: 15655711 [TBL] [Abstract][Full Text] [Related]